ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

The treatment, now available in England, targets myeloma, a blood cancer affecting plasma cells in the bone marrow. It ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is ...